Overview

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Phase:
PHASE3
Details
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Treatments:
sofosbuvir-velpatasvir drug combination